Susquehanna Portfolio Strategies LLC Trims Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Susquehanna Portfolio Strategies LLC trimmed its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 54.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 93,144 shares of the company’s stock after selling 112,856 shares during the period. Susquehanna Portfolio Strategies LLC’s holdings in GoodRx were worth $727,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cornercap Investment Counsel Inc. grew its holdings in shares of GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after purchasing an additional 1,266 shares during the period. California State Teachers Retirement System boosted its stake in GoodRx by 5.1% during the first quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock worth $503,000 after buying an additional 3,444 shares during the period. US Bancorp DE boosted its stake in GoodRx by 3.7% during the first quarter. US Bancorp DE now owns 109,818 shares of the company’s stock worth $780,000 after buying an additional 3,877 shares during the period. Beacon Capital Management LLC acquired a new stake in shares of GoodRx during the first quarter valued at about $28,000. Finally, Plato Investment Management Ltd purchased a new stake in shares of GoodRx in the 2nd quarter valued at approximately $43,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Analyst Ratings Changes

GDRX has been the subject of a number of research analyst reports. Morgan Stanley increased their price objective on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research report on Monday, June 10th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a research note on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of GoodRx in a report on Friday, August 16th. UBS Group dropped their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Finally, Citigroup reduced their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.36.

GoodRx Stock Performance

Shares of GDRX stock opened at $6.85 on Friday. The company has a market cap of $2.60 billion, a P/E ratio of -684.32, a PEG ratio of 3.38 and a beta of 1.38. The firm has a fifty day moving average price of $7.81 and a 200 day moving average price of $7.57. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96. GoodRx Holdings, Inc. has a 12 month low of $4.14 and a 12 month high of $9.26.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The company’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS. Sell-side analysts predict that GoodRx Holdings, Inc. will post 0.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.17% of the stock is owned by corporate insiders.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.